GHRP-6
Also known as: Growth Hormone Releasing Peptide 6, Growth Hormone Releasing Hexapeptide
GHRP-6 is a synthetic hexapeptide that stimulates growth hormone release through the ghrelin receptor. It was one of the first growth hormone releasing peptides developed.
Key Findings at a Glance
- • GHRP-6 causes near-universal appetite stimulation through potent ghrelin receptor activation in the hypothalamus, an effect strong enough to confound metabolic research designs.
- • GHRP-6 was the first synthetic growth hormone secretagogue discovered, paving the way for the entire GHRP family including GHRP-2, Hexarelin, and Ipamorelin.
- • GHRP-6 raises cortisol and prolactin levels in addition to growth hormone, distinguishing it from more selective secretagogues and limiting its utility in isolated GH research.
- • Research shows GHRP-6 has cytoprotective effects on gastric mucosa independent of its GH-releasing activity, sharing unexpected overlap with gut-protective peptides like BPC-157.
GHRP-6 Overview & Molecular Profile
GHRP-6 is a synthetic hexapeptide met-enkephalin analog that acts as a potent GHSR-1a agonist to stimulate growth hormone release. Developed by Bowers et al. in the 1980s, it was among the first synthetic GH secretagogues and helped establish the ghrelin receptor years before ghrelin was identified. GHRP-6 is the most appetite-stimulating GHRP family member due to strong hypothalamic ghrelin-mimetic activity, and it elevates cortisol and prolactin at higher doses. No approved clinical indication exists as of 2026.
Mechanism of Action: Hormonal Signaling & Receptor Binding
GHRP-6 acts as a ghrelin receptor (GHSR-1a) agonist, stimulating GH release from the pituitary gland. Unlike GHRH, it works through a different receptor and signaling pathway, allowing for synergistic effects when combined. GHRP-6 also stimulates hunger through its ghrelin-mimetic effects on appetite centers. It can stimulate the release of cortisol and prolactin at higher doses, though to a lesser extent than some other GHRPs.
Research-Observed Effects
Growth Hormone Release
Extensive ResearchResearch demonstrates GHRP-6 produces robust, dose-dependent increases in growth hormone levels through direct activation of the growth hormone secretagogue receptor (GHSR-1a) located on pituitary somatotroph cells. Clinical studies show peak GH concentrations occurring 15-30 minutes after subcutaneous administration, with increases of 5-15 fold above baseline depending on dosage and individual response variability. GHRP-6 stimulates GH release through mechanisms independent of growth hormone releasing hormone (GHRH), allowing for synergistic effects when these compounds are combined in research protocols for growth hormone deficiency treatment studies. The peptide works by amplifying the natural pulsatile pattern of GH secretion rather than creating sustained unphysiological elevations, which is considered advantageous for maintaining normal feedback regulation. Research has documented GHRP-6's effectiveness in various populations including elderly subjects where natural GH production is diminished, making it valuable for age-related growth hormone decline research and sarcopenia prevention studies.
Appetite Stimulation
Extensive ResearchGHRP-6 produces the most pronounced appetite stimulation among growth hormone releasing peptides due to its strong ghrelin-mimetic activity at hypothalamic appetite control centers, with research subjects reporting significant hunger increases within 20-30 minutes of administration. Studies demonstrate that GHRP-6 activates the same GHSR-1a receptors that natural ghrelin uses to signal hunger, triggering orexigenic (appetite-stimulating) neuropeptide release including NPY (neuropeptide Y) and AgRP (agouti-related peptide) in the arcuate nucleus. This robust appetite stimulation research application makes GHRP-6 particularly valuable for studying feeding behavior mechanisms, cachexia treatment approaches, and metabolic disorders characterized by appetite dysregulation. Research in anorexia and cancer-related cachexia models shows GHRP-6 can significantly increase food intake and body weight gain, with some studies documenting 20-40% increases in caloric consumption. The appetite effects, while sometimes considered a side effect in general GH research, provide unique opportunities for investigating the gut-brain axis, satiety signaling pathways, and hunger hormone physiology.
Gastric Motility
Moderate ResearchStudies demonstrate GHRP-6's significant effects on gastrointestinal function through ghrelin pathway activation, including accelerated gastric emptying, enhanced intestinal peristalsis, and increased gastric acid secretion. Research in gastroparesis models shows GHRP-6 administration can improve gastric emptying time by 30-50%, suggesting potential diabetic gastroparesis treatment applications and post-operative ileus prevention studies. The peptide stimulates the migrating motor complex (MMC), the coordinated intestinal contractions that occur between meals to sweep debris through the digestive tract, with implications for small intestinal bacterial overgrowth (SIBO) research. GHRP-6's prokinetic effects appear mediated through both direct smooth muscle stimulation and indirect effects via the enteric nervous system and vagal pathways. These gastrointestinal effects have positioned GHRP-6 as a valuable research tool for studying gut motility disorders, functional dyspepsia mechanisms, and the relationship between growth hormone signaling and digestive function.
Cardioprotective Research
Preliminary ResearchEmerging research suggests GHRP-6 may possess cardioprotective properties through mechanisms potentially independent of growth hormone release, including direct effects on cardiac myocytes and vascular endothelial cells. Studies in ischemia-reperfusion injury models demonstrate reduced infarct size, improved left ventricular function, and decreased cardiomyocyte apoptosis following GHRP-6 treatment, with some studies showing up to 40% reduction in infarct area. Research indicates the peptide may activate cardioprotective signaling cascades including the PI3K/Akt pathway and reduce oxidative stress markers in cardiac tissue. GHRP-6 has been studied for effects on cardiac fibrosis, with some research suggesting reduced collagen deposition and improved ventricular compliance in heart failure models. These cardiovascular research applications have generated interest in GHRP-6 for coronary artery disease studies, post-myocardial infarction recovery research, and investigations into peptide-based cardioprotection strategies.
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. GHRP-6 is not approved for human use by the FDA or any regulatory agency. This information is provided for research reference only and does not constitute a dosing recommendation.
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous | 1–3 mcg/kg | 1–3× daily | Most common research route; peak GH at 15–30 min |
| Intravenous | 1–3 mcg/kg | Single dose | Used in PK/PD human studies |
| Intraperitoneal | 1–3 mcg/kg | Daily | Rodent metabolic and cardioprotection models |
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
Growth hormone releasing peptides
Bowers CY
Journal of Clinical Endocrinology & Metabolism (1998)
This landmark review by Dr. Cyril Bowers, the pioneer who discovered growth hormone releasing peptides in the 1970s, provides comprehensive analysis of GHRP-6 and related compounds' mechanisms, pharmacology, and clinical potential. The paper details the discovery process that led to identification of the ghrelin receptor pathway and explains how GHRP-6 stimulates GH release through mechanisms distinct from and synergistic with growth hormone releasing hormone. Dr. Bowers presents extensive pharmacokinetic data showing dose-response relationships, peak GH levels occurring 15-30 minutes post-administration, and the duration of GH elevation in various study populations. The review examines GHRP-6's effects on other pituitary hormones including modest increases in ACTH, cortisol, and prolactin at higher doses, contrasting this with more selective newer peptides. This foundational work established GHRP-6 as a critical research tool for understanding growth hormone physiology and laid groundwork for clinical applications in growth hormone deficiency treatment and anti-aging research.
GHRP-6 effects on food intake and gastrointestinal motility
Asakawa A, Inui A, et al.
Regulatory Peptides (2003)
This study investigated GHRP-6's orexigenic (appetite-stimulating) effects and gastrointestinal motility changes in rodent models, providing mechanistic insight into its ghrelin-mimetic properties. Researchers demonstrated that peripheral and central administration of GHRP-6 significantly increased food intake in a dose-dependent manner, with peak effects occurring 30-60 minutes after injection. The study documented that GHRP-6's appetite-stimulating effects were abolished in ghrelin receptor knockout mice, confirming the GHSR-1a receptor as the primary mediator. Gastric emptying studies revealed accelerated solid meal transit times of approximately 35% compared to controls, suggesting therapeutic potential for gastroparesis research. Additionally, the research identified increased expression of orexigenic neuropeptides NPY and AgRP in the hypothalamus following GHRP-6 treatment, establishing the neuroendocrine pathway underlying appetite stimulation and providing foundation for cachexia treatment studies.
Cardioprotective effects of GHRP-6 in experimental myocardial infarction
Berlanga J, Cibrian D, et al.
Life Sciences (2007)
This preclinical study examined GHRP-6's cardioprotective properties in a rat model of ischemia-reperfusion injury, demonstrating significant heart-protective effects potentially independent of growth hormone release. Researchers subjected rats to 30-minute coronary artery occlusion followed by reperfusion and treated experimental groups with GHRP-6 at the time of reperfusion. Results showed approximately 40% reduction in infarct size, significantly improved left ventricular developed pressure, and reduced cardiac enzyme release (creatine kinase and troponin) in treated animals. The study identified activation of pro-survival kinases including Akt and reduced levels of pro-apoptotic markers in cardiac tissue. Importantly, the cardioprotective effects were observed at doses that did not significantly elevate circulating GH levels, suggesting direct cardiac mechanisms. These findings positioned GHRP-6 as a candidate for adjunctive treatment studies for acute myocardial infarction and stimulated investigation into peptide-based cardioprotection strategies.
Comparative Research
Explore in-depth research analyses and comparative studies featuring GHRP-6.
Frequently Asked Questions
What makes GHRP-6 unique compared to Ipamorelin and GHRP-2?
GHRP-6 was one of the earliest synthetic GH secretagogues and is notable for producing the most pronounced appetite stimulation of any GHRP. This is because GHRP-6 has the highest intrinsic activity at hypothalamic ghrelin receptors controlling orexigenic (appetite-stimulating) neuropeptide release. It also more significantly elevates cortisol and prolactin compared to Ipamorelin or GHRP-2. These properties make GHRP-6 valuable for research specifically studying appetite mechanisms, cachexia, and ghrelin's role in hunger—but less ideal for isolated GH research where hormonal confounders complicate interpretation.
Why does GHRP-6 increase appetite?
GHRP-6 mimics ghrelin's action at the GHSR-1a receptor in the hypothalamus, specifically at neurons in the arcuate nucleus that release NPY (neuropeptide Y) and AgRP (agouti-related peptide)—powerful appetite-stimulating signals. Natural ghrelin rises before meals and triggers hunger through this exact mechanism. GHRP-6's strong agonism at this receptor means appetite increases are common within 20–30 minutes of administration. Ipamorelin activates the same receptor but has much lower intrinsic activity at the hypothalamic level, producing minimal appetite effects.
Does GHRP-6 have cardioprotective effects?
Preclinical evidence suggests yes. Studies in rodent ischemia-reperfusion models show GHRP-6 reduces infarct size by approximately 40%, improves left ventricular function, and activates cardioprotective PI3K/Akt signaling pathways—effects observed at doses not significantly elevating systemic GH. This suggests direct cardiac mechanisms independent of GH release. The cardioprotective research is preliminary and conducted exclusively in animal models; no human cardiac trials for GHRP-6 have been published.
How does GHRP-6 compare to GHRP-2?
Both are GHSR-1a agonists, but GHRP-2 produces greater GH release per microgram with less appetite stimulation and less cortisol/prolactin elevation compared to GHRP-6. GHRP-2 is generally preferred when maximum GH stimulation is desired with fewer off-target effects. GHRP-6 is preferred when appetite stimulation is part of the research objective (cachexia, anorexia models) or when the full ghrelin-mimetic profile is of interest.
Does GHRP-6 affect the gastrointestinal tract?
Yes. GHRP-6 activates ghrelin receptors in the gastrointestinal tract, accelerating gastric emptying, stimulating the migrating motor complex, and increasing gastric acid secretion. Research shows 30–50% improvement in gastric emptying in gastroparesis models. Additionally, GHRP-6 has been shown to provide cytoprotective effects on gastric mucosa through mechanisms overlapping with BPC-157 research. These GI effects make GHRP-6 relevant for gastroparesis and gut motility research.
What is GHRP-6's historical significance in peptide research?
GHRP-6 was developed by Cyril Bowers and colleagues in the 1980s as part of efforts to find synthetic analogs that could stimulate GH release. Research on GHRP-6 and related compounds helped establish that there must be an endogenous receptor for this class of molecules—an insight that preceded the actual discovery of ghrelin by Kojima and colleagues in 1999. GHRP-6 essentially helped predict ghrelin's existence and identify its receptor before the hormone was isolated, making it historically significant in endocrinology.
Can GHRP-6 be combined with GHRH or CJC-1295?
Yes—GHRP-6 and GHRH (or CJC-1295) work through completely different receptors and produce strongly synergistic GH release when combined. GHRH amplifies the GH pulse amplitude by priming pituitary somatotrophs, while GHRP-6 acts on the GHSR-1a receptor to both trigger and sustain GH release. Combined administration in clinical studies produces 3–5× greater GH area-under-curve than either compound alone. This synergy is the pharmacological rationale behind popular research combinations like GHRP-6 + CJC-1295. The combination must account for GHRP-6's appetite and cortisol elevations when interpreting results.
What is the half-life of GHRP-6 and how does this affect dosing?
GHRP-6 has a short plasma half-life of approximately 15–60 minutes, with peak GH elevations occurring 15–30 minutes post-injection and returning to baseline within 2–3 hours. This rapid clearance necessitates frequent dosing if consistent GH stimulation is the research goal. The short half-life also means appetite stimulation and hormonal effects are transient, typically resolving within 90–120 minutes. Subcutaneous injection produces slower absorption than IV, slightly prolonging the effect window. This pharmacokinetic profile is characteristic of all non-acylated GHRP peptides.
Related Peptides
View allIpamorelin
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin levels.
GHRP-2
GHRP-2 is a synthetic growth hormone secretagogue that stimulates GH release through the ghrelin receptor. It is considered one of the most potent GHRPs for GH stimulation.
Hexarelin
Hexarelin is a synthetic growth hormone secretagogue and one of the most potent GHRPs. It has been studied for cardioprotective effects in addition to GH release properties.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) with a Drug Affinity Complex that extends its half-life significantly compared to native GHRH.